Drugs / CD25hi Treg depleted DLI
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03912064 Background | Jul 2019 → May 2024 overdue | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome, myelofibrosis | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD25hi Treg depleted DLI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03912064 ↗ |
| Modality | Cell therapy | “Donor lymphocyte product” NCT03912064 ↗ |
| Route | Intravenous | “Patients will receive a defined dose of CD25hi Treg depleted DLI intravenously” NCT03912064 ↗ |